Edition:
United Kingdom

XBiotech Inc (XBIT.OQ)

XBIT.OQ on NASDAQ Stock Exchange Global Select Market

4.44USD
3:44pm GMT
Change (% chg)

$0.28 (+6.73%)
Prev Close
$4.16
Open
$4.50
Day's High
$4.50
Day's Low
$4.32
Volume
29,245
Avg. Vol
37,647
52-wk High
$20.18
52-wk Low
$2.80

Chart for

About

XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): $157.97
Shares Outstanding(Mil.): 35.42
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 84.57 16.44
EPS (TTM): -- -- --
ROI: -- 3.42 10.61
ROE: -- 5.38 14.21

BRIEF-XBIOTECH ‍ENROLLS FIRST PATIENT IN STUDY EVALUATING MABP1 IN WITH ONIVYDE

* ‍ENROLS FIRST PATIENT IN STUDY EVALUATING MABP1 IN COMBINATION WITH ONIVYDE & 5-FLUOROURACIL/FOLINIC ACID FOR TREATMENT OF PANCREATIC CANCER​ Source text for Eikon: Further company coverage:

18 Oct 2017

BRIEF-XBiotech announces agreement with Cedars-Sinai Medical Center to evaluate MABP1 combination for the treatment of pancreatic cancer

* Xbiotech announces agreement with Cedars-Sinai Medical Center to evaluate MABP1 in combination with Onivyde and 5-fluorouracil/folinic acid for the treatment of pancreatic cancer Source text for Eikon: Further company coverage:

20 Sep 2017

BRIEF-XBiotech - European Medicines Agency maintains its May 18, 2017 opinion

* XBiotech - on Sept 14, although there were advancements in certain areas of application European Medicines Agency has maintained its May 18, 2017 opinion

15 Sep 2017

Earnings vs. Estimates